Please wait while we load the requested 10-Q report or click the link below:
OncoMed Announces Third Quarter 2018 Financial Results and Operational Highlights
-Company continues enrollment in Phase 1b navicixizumab trial following encouraging single agent and interim combination results in ovarian cancer;
-Prepares for presentation of etigilimab data at Society for Immunotherapy of Cancer (SITC) Annual Meeting
REDWOOD CITY, Calif., November 1, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced third quarter 2018 financial results and provided a corporate update. As of September 30, 2018, cash, cash equivalents, and short-term investments totaled $70.9 million.
"As anticipated, our development efforts have culminated in a stream of data this year and set the stage for additional data flow in 2019,” said John Lewicki, Ph.D., President and Chief Executive Officer of OncoMed. “The efficacy of navicixizumab, both as a single agent and in combination with chemotherapy, has been impressive in patients with heavily pretreated, late stage recurrent ovarian cancer. We continue to enroll additional patients in our ongoing Phase 1b clinical trial as we consider the possible next steps for this program. Concurrently, clinical investigation and proof of concept continues for our other clinical candidates: etigilimab (anti-TIGIT) and GITRL-Fc in metastatic solid tumor settings.”
Navicixizumab (anti-DLL4/VEGF bispecific; OMP-305B83)
The following information was filed by Oncomed Pharmaceuticals Inc (OMED) on Thursday, November 1, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Oncomed Pharmaceuticals Inc's financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Oncomed Pharmaceuticals Inc.